Cash is simply king during times of high market volatility and deep global economic uncertainty. With the rampant spread of COVID-19, many companies have seen their stock prices plunge due to hardships, while others have seen their shares skyrocket as they work toward developing solutions to end the deadly pandemic.
This market has created ample opportunities to buy reputable businesses at a bargain price, and it's also given investors the chance to buy solid growth companies at a high price with an eye to selling even higher. Those with unallocated capital in their investment portfolios who act decisively can often reap high rewards.
Today, let's look at two healthcare companies -- a value stock and a growth stock -- that, while they have been oppositely affected by the COVID-19 pandemic, have one thing in common: the ability to reward investors who act now.